These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19749494)

  • 1. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
    Sasaki H; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohhira M; Oyama T; Miyashita Y; Shirai K
    J Atheroscler Thromb; 2009 Oct; 16(5):568-75. PubMed ID: 19749494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
    Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
    Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
    Miyashita Y; Saiki A; Endo K; Ban N; Yamaguchi T; Kawana H; Nagayama D; Ohira M; Oyama T; Shirai K
    J Atheroscler Thromb; 2009 Oct; 16(5):621-6. PubMed ID: 19907103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients.
    Nakano N; Ishimitsu T; Takahashi T; Inada H; Okamura A; Ohba S; Matsuoka H
    Int Heart J; 2010 May; 51(3):188-92. PubMed ID: 20558909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Suzuki H; Fujii Y; Ito M; Yoshida Y; Okada K; Soma M
    Hypertens Res; 2012 Aug; 35(8):874-81. PubMed ID: 22592665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
    Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
    Ogura C; Ono K; Miyamoto S; Ikai A; Mitani S; Sugimoto N; Tanaka S; Fujita M
    Blood Press; 2012 Dec; 21(6):367-71. PubMed ID: 22747420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
    Takai S; Jin D; Sakonjo H; Miyazaki M
    Hypertens Res; 2010 Sep; 33(9):953-9. PubMed ID: 20520612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension.
    Tanaka T; Tsutamoto T; Sakai H; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2007 Aug; 30(8):691-7. PubMed ID: 17917316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension.
    Oshima T; Ozono R; Yano Y; Higashi Y; Teragawa H; Miho N; Ishida T; Ishida M; Yoshizumi M; Kambe M
    Hypertens Res; 2005 Nov; 28(11):889-94. PubMed ID: 16555577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Iwasaka T
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Ando K; Ueshima K; Tanaka S; Kosugi S; Sato T; Matsuoka H; Nakao K; Fujita T
    Int J Med Sci; 2013; 10(9):1209-16. PubMed ID: 23935398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
    Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
    Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T;
    Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels.
    Tanaka H; Shigenobu K
    Cardiovasc Drug Rev; 2002; 20(1):81-92. PubMed ID: 12070536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells.
    Imagawa K; Okayama S; Takaoka M; Kawata H; Naya N; Nakajima T; Horii M; Uemura S; Saito Y
    J Cardiovasc Pharmacol; 2006 Jan; 47(1):133-8. PubMed ID: 16424797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-type Ca channel blockade as a determinant of kidney protection.
    Hayashi K; Homma K; Wakino S; Tokuyama H; Sugano N; Saruta T; Itoh H
    Keio J Med; 2010; 59(3):84-95. PubMed ID: 20881449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium.
    Tanaka H; Komikado C; Shimada H; Takeda K; Namekata I; Kawanishi T; Shigenobu K
    J Pharmacol Sci; 2004 Dec; 96(4):499-501. PubMed ID: 15599089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.